Corline Biomedical: Q4 Review
Research Note
2021-03-01
10:08
Redeye reiterates its positive view and Base case of SEK 39 per share following Corline’s Q4 report. We provide a brief comment on the financials and highlight the most important events during the period.
LS
Ludvig Svensson
Disclosures and disclaimers